Evaluates corrected hemoglobin A1c for measuring short-term glycemic control in diabetes, suggesting its clinical validity.
The corrected hemoglobin A1c(cHbA1c) value was calculated on the basis of HbA1c data obtained over 4 months in 19 patients with type 2 diabetes. The usefulness of cHbA1c as a short-term glycemic control index was compared with that of glycated albumin. Both the HbA1c value (measured by immunoassay) and the calculated cHbA1c value showed significant positive correlations with glycated albumin. However, cHbA1c showed a stronger correlation with glycated albumin. In each patient,the variation of cHbA1c values was also more marked than that of HbA1C. However, neither HbA1c nor cHbA1c was able to closely reflect blood glucose changes in patients with unstable glycemic change. In conclusion, cHbA1c may be a useful measure of the weighted mean blood glucose over the preceding one month in patients with comparatively slow changes of blood glucose level.
No takes yet. Share an insight, caveat, or question.
A 2002 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: